Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
822.00    8.00 (0.98%)
Bid:
812.00
Ask:
818.00
Spread: 6.00 (0.739%)
Market Cap: £378.91m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Acquisition and Trading Update

5 Jun 2013 07:00

RNS Number : 2950G
Porvair PLC
05 June 2013
Β 

For immediate release 5 June 2013

Β 

Porvair plc ("Porvair" or "The Group")

Β 

Acquisition and Trading Update

Β 

Porvair, the specialist filtration and environmental technologies group, today announces the acquisition of the business of Eisenmann Metallurgical LLC and issues a trading update ahead of the publication of its interim results for the six months ended 31 May 2013 on 24 June 2013.

Β 

The Group's Microfiltration division has acquired the goodwill, business and trading assets of Eisenmann Metallurgical LLC, trading as Chand Eisenmann Metallurgical ("CEM"), for a total consideration of US$5.5 million in cash and loans. CEM designs and manufactures specialist filters from a facility in Caribou, Maine. There is a good commercial fit between CEM and Porvair's existing product portfolio. With clear cross-selling opportunities, the combined business is well positioned to accelerate its rate of growth in the US. The transaction is expected to be immediately earnings accretive.

Β 

The Group has started 2013 well and expects to report interim profits well ahead of 2012. Several major contracts were announced earlier in the year and will support Group performance over the next few years. All are on schedule and have begun to contribute to results. Group revenue is expected to be around 7% ahead of the first six months of 2012 at constant currency rates. Order books are strong in Microfiltration and market share gains continue to be made in Metals Filtration.

Β 

An analyst briefing will be held at 9.30 a.m. at Buchanan, 107 Cheapside, London, EC2V 6DN on the day of the interim results, Monday 24 June 2013.

Β 

Commenting on the acquisition and trading, Ben Stocks, Chief Executive, said:

Β 

"CEM is a highly complementary bolt-on acquisition which broadens our product range, geographic spread and materials expertise. Its staff, based in Caribou, Maine, are skilled and highly experienced and are warmly welcomed to the Group. There are many cross-selling opportunities apparent in this transaction and we plan to invest in the Caribou facility over the next 12 months to accommodate the expected growth.

Β 

Trading in the first half of 2013 has been satisfactory, and the prospects for the second half; supported by our order books, recent large engineering contracts, and the CEM acquisition; are good."

Β 

For more information, contact:

Β 

Porvair plc

Ben Stocks, Chief Executive

01553 765 500

Chris Tyler, Group Finance Director

01553 765 500

Buchanan

0207 466 5000

Charles Ryland / Helen Greenwood / Clare Akhurst

www.buchanan.uk.com

Β 

Β 

Notes to Editors

Porvair is a group of specialist filtration and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. Its principal markets are aviation, energy and industrial process, environmental laboratories and non-ferrous metals.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCUSANROBANRAR
Date   Source Headline
27th Mar 20257:00 amRNSGrant of SAYE Options
18th Mar 20257:40 amRNSHolding(s) in Company
17th Mar 20253:30 pmRNSHolding(s) in Company
14th Mar 20257:00 amRNSNotice of Annual General Meeting; Accounts posting
4th Mar 20253:00 pmRNSHolding(s) in Company
12th Feb 20252:30 pmRNSDirector/PDMR Shareholding
10th Feb 20257:00 amRNSFull Year Results
12th Dec 20241:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSTrading update and notice of results
2nd Dec 20243:01 pmRNSTotal Voting Rights
2nd Dec 20243:00 pmRNSDirector/PDMR Shareholding
25th Nov 20244:37 pmRNSShareholder Communications
28th Oct 20247:00 amRNSBoard appointment
1st Oct 20247:00 amRNSTotal Voting Rights
23rd Sep 20247:00 amRNSAppointment of Chief Executive Officer
2nd Sep 20245:15 pmRNSDirector/PDMR Shareholding
2nd Sep 20245:00 pmRNSTotal Voting Rights
31st Jul 202410:45 amRNSTotal Voting Rights
31st Jul 202410:30 amRNSBlock listing Interim Review
29th Jul 20246:15 pmRNSDirector/PDMR Shareholding
1st Jul 20247:00 amRNSInterim Results
27th Jun 20242:26 pmRNSDirector/PDMR Shareholding
23rd Apr 20241:38 pmRNSDirector/PDMR Shareholding
16th Apr 20242:56 pmRNSAGM Results Announcement
16th Apr 20247:00 amRNSAGM Trading Update & Board Update
3rd Apr 20247:00 amRNSDirector resignation
12th Mar 20247:00 amRNSDirector declaration
29th Feb 20247:00 amRNSTotal Voting Rights
8th Feb 20244:41 pmRNSHolding(s) in Company
8th Feb 20244:27 pmRNSDirector/PDMR Shareholding
5th Feb 20247:00 amRNSResults for the year ended 30 November 2023
1st Feb 20247:00 amRNSBlock listing Interim Review
19th Dec 202310:25 amRNSHolding(s) in Company
5th Dec 20237:00 amRNSTrading Update & Acquisition
4th Dec 202312:00 pmRNSHolding(s) in Company
25th Sep 202310:00 amRNSDirector/PDMR Shareholding
12th Sep 20237:00 amRNSNine Month Trading Update
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
17th Jul 20237:00 amRNSAcquisition completion
7th Jul 20234:00 pmRNSBlock Listing Application
3rd Jul 20237:00 amRNSInterim Results
26th Jun 20237:00 amRNSBoard Change
21st Jun 20234:22 pmRNSHolding(s) in Company
21st Jun 20237:00 amRNSDirector/PDMR Shareholding
15th Jun 20237:00 amRNSBlock listing Interim Review
4th May 20237:00 amRNSAcquisitions
18th Apr 202312:51 pmRNSAGM resolutions
18th Apr 20237:00 amRNSAGM Trading Update
31st Mar 20234:00 pmRNSTotal Voting Rights
22nd Mar 20233:03 pmRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.